Emerging therapies for melanoma

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19(16), 3635–3648 (2001).
   PubMed Web of Science ®Google Scholar
• Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med.355(13), 1307–1317 (2006).
   PubMed Web of Science ®Google Scholar
• Carlson GW, Murray DR, Hestley A et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it? Ann. Surg. Oncol.10(4), 408–415 (2003).
   PubMedGoogle Scholar
• Ra JH, McMasters KM, Spitz FR. Should all melanoma patients undergo sentinel lymph node biopsy? Curr. Opin. Oncol.18(2), 185–188 (2006).
   PubMedGoogle Scholar
• Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ 3rd. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann. Surg. Oncol.13(7), 927–932 (2006).
   PubMedGoogle Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol.14(1), 7–17 (1996).
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23(35), 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA100(14), 8372–8377 (2003).
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol.12(12), 1005–1016 (2005).
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P et al. Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol.23(4), 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine25(Suppl. 2), B4–B16 (2007).
   PubMed Web of Science ®Google Scholar
• Fay JW, Palucka AK, Paczesny S et al. Long-term survival in patients with metastatic melanoma vaccinated with melanoma-antigen loaded dendritic cells. J. Clin. Oncol.25(18 Suppl.), 8547 (2007).
   Google Scholar
• Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res.12(7 Pt 2), S2331–S2336 (2006).
   PubMed Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF et al. An international, randomized, Phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. MMAIT Clinical Trials Group. J. Clin. Oncol.25(18 Suppl.), 8508 (2007).
   Web of Science ®Google Scholar
• Wheatley K, Hancock B, Gore M et al. on behalf of International Malignant Melanoma Collaborative Group. Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J. Clin. Oncol.25(18 Suppl.), 8526 (2007).
   Google Scholar
• Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon α-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol.24(19), 3164–3171 (2006).
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol.18(8), 1614–1621 (2000).
   PubMed Web of Science ®Google Scholar
• Patel TA, Baweja M, Maples W, Markovic SN. Granulocyte macrophage colony stimulating factor as adjuvant therapy for resected stage III/IV melanoma: retrospective review of a single institutional experience. J. Clin. Oncol.25(18 Suppl.), 19002 (2007).
   Google Scholar
• Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl Acad. Sci. USA101(Suppl. 2), 14639–14645 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314(5796), 126–129 (2006).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• McDermott DF Sosman J, Cranmer FL et al. Randomized Phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.), 8511 (2007).
   Google Scholar
• Flaherty KT Brose M, Schluchter L et al. Phase I/II trial of BAY 43–9006, carboplatin (C) and paclitaxel (P) demonstrate preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. ASCO Annual Meeting Proceedings. J. Clin. Oncol.22(14 Suppl.), 7507 (2004).
   Google Scholar
• Agarwala S, Keilholz U, Hauschild A et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol.25(18 Suppl.), 8510 (2007).
   Web of Science ®Google Scholar
• Rao R, Allred, JB, Markovic, SN et al. Results of NCCTG Phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J. Clin. Oncol.25(18 Suppl.), 8530 (2007).
   Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24(29), 4738–4745 (2006).
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H et al. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res.16(5), 405–411 (2006).
   PubMed Web of Science ®Google Scholar
• Perez D, Suman V, Amatruda T et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. J. Clin. Oncol.25(18 Suppl.), 8560 (2007).
   Google Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood101(12), 4878–4886 (2003).
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Spieth K, Leiter U et al. Temozolomide in combination with interferon-a versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, Phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J. Clin. Oncol.23(35), 9001–9007 (2005).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol.25(3), 283–286 (2002).
   PubMed Web of Science ®Google Scholar
• Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res.13(5), 531–536 (2003).
   PubMed Web of Science ®Google Scholar
• Rao RD, Holtan SG, Ingle JN et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer106(2), 375–382 (2006).
   PubMed Web of Science ®Google Scholar
• Salgia R, Berkenblit A, Dezube B, Dahl TA. STA-4783, a novel HSP inducer, enhances paclitaxel activity—preclinical to clinical modeling. J. Clin. Oncol.22(14 Suppl.), 3124 (2004).
   Google Scholar
• Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol.24(15), 2283–2289 (2006).
   PubMed Web of Science ®Google Scholar
• Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother.28(6), 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson MR, Chan CC, Yang JC et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother.27(6), 478–479 (2004).
   PubMed Web of Science ®Google Scholar
• Varker KA, Biber JE, Kefauver C et al. A randomized Phase II trial of bevacizumab with or without daily low-dose Interferon α-2b in metastatic malignant melanoma. Ann. Surg. Oncol.14(8), 2367–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhn MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol.3(7), 611–618 (2002).
   PubMed Web of Science ®Google Scholar